Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alisol B 23-acetate is a **natural protostane-type triterpenoid small molecule** isolated from *Alisma* species that has been investigated in preclinical research for metabolic disease, particularly obesity and related disorders. In the cited mouse study, it promoted white adipose tissue browning and improved high-fat diet-induced obesity, with reported activity linked to regulation of the **mTOR-SREBP1 signaling axis**. The compound appears to remain an experimental research-stage agent rather than a clinically developed pharmaceutical product, and no specific commercial developer, approved indication, or branded product could be reliably identified from the provided evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alisol b 23-acetate.